IVX
vs
S
S&P/ASX 300
IVX
Over the past 12 months, IVX has underperformed S&P/ASX 300, delivering a return of -69% compared to the S&P/ASX 300's +7% growth.
Stocks Performance
IVX vs S&P/ASX 300
Performance Gap
IVX vs S&P/ASX 300
Performance By Year
IVX vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Invion Ltd
Glance View
Invion Ltd. is a clinical-stage life sciences company, which engages in the research and development of treatments for market opportunities in a variety of cancer indications, chronic inflammatory, and autoimmune diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2010-02-15. The firm is focused on the development of Photosoft technology for the treatment of a range of cancers. The firm is conducting various clinical trials for the development of its Photosoft technology. Its Photo Dynamic Therapy (PDT) is a treatment that optimizes the use of non-toxic photosensitizers and visible light to kill cancer and stimulate the immune system. The firm aims to develop photosensitizer, IVX-PDT, that improves the treatment of skin cancers and hard-to-treat solid cancers, such as those present in ovarian, prostate and lungs. Epitech Dermal Science Pty Ltd is the wholly owned subsidiary of the Company.